Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development(1) | $36,053 | $20,023 |
| General and administrative(2) | 7,392 | 3,361 |
| Total operating expenses | 43,445 | 23,384 |
| Loss from operations | (43,445) | (23,384) |
| Other income (expense): | ||
| Interest income | 3,102 | 615 |
| Change in fair value of Convertible Notes payable(3) | — | (15,400) |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's G&A?
- Jade Biosciences (JBIO) reported G&A of $7.39M in Q1 2026.
- How has Jade Biosciences's G&A changed year-over-year?
- Jade Biosciences's G&A increased by 119.9% year-over-year, from $3.36M to $7.39M.
- What is the long-term trend for Jade Biosciences's G&A?
- Over 4 years (2021 to 2025), Jade Biosciences's G&A has grown at a 26.3% compound annual growth rate (CAGR), from $8.04M to $20.42M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Jade Biosciences's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude